Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective ...

The Trump administration recently nixed a rule proposed by President Biden that would have made it easier for 7.4 million ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...

Eli Lilly has launched Mounjaro in India, a once-weekly injection targeting both type 2 diabetes and obesity, priced at Rs 3,500 for a 2.5mg dose. This dual-action drug stimulates two key hormone ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Meghan Trainor has revealed she has Mounjaro to thank for her new look alongside diet and exercise but she's not the only one ...

The latest obesity contender, Antag Therapeutics A/S, has dosed the first participants in a phase I trial of a glucose-dependent insulinotrophic polypeptide (GIP) agonist it said will address key gaps ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...